Kinetics of Anti-Mannan Antibodies Useful in Confirming Invasive Candidiasis in Immunocompromised Patients

J-STAGE
  • Deventer A. Johanna M. van
    Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University School of Medicine
  • Goessens Wil H.F.
    Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University School of Medicine
  • Zeijl Jan H. van
    Department of Bacteriology, St. Laurentius Hospital
  • Mouton Jan W.
    Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University School of Medicine
  • Michel Marc F.
    Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University School of Medicine
  • Verbrugh Henri A.
    Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University School of Medicine

抄録

In studying the anti-mannan antibodies longitudinally in serial serum samples of three immunocompromised patients, it was observed that anti-mannan antibodies started to increase shortly after the moment that cultures of deep-tissue sites became positive with Candida albicans. The mean anti-mannan antibody titers determined in a group of 36 immunocompromised patients with invasive candidiasis increased within two weeks after the probable onset of invasive candidiasis. In contrast, anti-mannan antibody levels in serial serum samples of 14 immunocompromised patients who were only colonized with C. albicans remained stable or decreased over time. The HA test measuring the anti-mannan antibodies was 64% sensitive and 89% specific in determining invasive candidiasis. In contrast, antibodies specific for candidal cytoplasmic antigens or enolase alone were of little value in confirming invasive candidiasis in these immunocompromised patients.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ